AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...

as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to ...

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...

Granulomatosis with polyangiitis (GPA), or Wegener’s granulomatosis ... pain in joints or muscles, and rash on the skin. It can be challenging to get a vasculitis diagnosis, especially when the ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

Further history-taking revealed joint pain in the patient’s hand and shoulders, as well as the presence of pinpoint superficial pruritic skin rash. The patient ... treated for possible AAV of the ...

It might be used, for example, as part of initial treatment for severe GPA-type vasculitis (granulomatosis with polyangiitis vasculitis), along ... mild hair loss, rash, fatigue, or headache. Although ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.